Gemini Therapeutics, Inc. (NASDAQ:GMTX - Get Free Report)'s stock price hit a new 52-week high on Monday . The stock traded as high as $31.92 and last traded at $31.78, with a volume of 504478 shares traded. The stock had previously closed at $30.10.
Gemini Therapeutics Trading Up 5.6 %
The company has a market cap of $1.38 billion, a price-to-earnings ratio of -1.35 and a beta of -0.12. The company has a fifty day moving average price of $62.55 and a two-hundred day moving average price of $56.33.
Hedge Funds Weigh In On Gemini Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its position in shares of Gemini Therapeutics by 3.5% during the 1st quarter. BlackRock Inc. now owns 1,300,204 shares of the company's stock worth $1,807,000 after buying an additional 43,831 shares during the period. Millennium Management LLC raised its position in Gemini Therapeutics by 42.1% in the 2nd quarter. Millennium Management LLC now owns 762,163 shares of the company's stock valued at $1,288,000 after purchasing an additional 225,961 shares during the last quarter. Renaissance Technologies LLC raised its position in Gemini Therapeutics by 2,850.4% in the 1st quarter. Renaissance Technologies LLC now owns 351,100 shares of the company's stock valued at $488,000 after purchasing an additional 339,200 shares during the last quarter. Bank of Montreal Can bought a new position in Gemini Therapeutics in the 2nd quarter valued at $276,000. Finally, UBS Group AG bought a new position in Gemini Therapeutics in the 2nd quarter valued at $234,000. Institutional investors own 75.42% of the company's stock.
About Gemini Therapeutics
(
Get Free Report)
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gemini Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gemini Therapeutics wasn't on the list.
While Gemini Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
